The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all asset purchase deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of asset purchase deals. The chapter includes numerous case studies to enable understanding of both pure asset purchase deals and multicomponent deals where asset purchase forms a part.

Chapter 4 provides a review of the leading asset purchase deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of asset purchase deals signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.

In addition the report includes a comprehensive listing of all asset purchase deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:

In-depth understanding of asset purchase deal trends since 2009
Analysis of the structure of asset purchase agreements with numerous real life case studies
Comprehensive access to over 1,000 actual asset purchase deals entered into by the world’s biopharma companies
Detailed access to actual asset purchase deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a asset purchase agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

Trends in asset purchase dealmaking in the biopharma industry since 2009
Analysis of asset purchase deal structure
Case studies of real-life asset purchase deals
Access to over 1,000 asset purchase deal records
The leading asset purchase deals by value since 2009
Most active asset purchase dealmakers since 2009
The leading asset purchase partnering resources

In Asset Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Table Of Contents

TABLE OF CONTENTS

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in asset purchase deals since 2009
2.3. Reasons for entering into asset purchase partnering deals
2.3.1. Business assets
2.3.2. Product assets
2.3.3. Royalty assets
2.3.4.Technology assets
2.4 The emergence of royalty asset purchase deals
2.4.1. Primary players in royalty asset purchase deals
2.4.2. Recent leading royalty asset purchase deals
2.4.3. The future of royalty asset purchase deals
2.5. The role of IP auction houses in asset purchase deals
2.5.1. Leading IP auction companies
2.6. The future of asset purchase agreements

Chapter 3 - Overview of asset purchase deal structure

3.1. Introduction
3.2. Asset purchase agreement structure
3.3. Example asset purchase agreements
3.3.1. Case study 1: Product asset: QLT - Valeant Pharmaceuticals
3.3.2. Case study 2: Business asset: Enzon Pharmaceuticals - Sigma-Tau
3.4. Anatomy of a royalty asset purchase agreement
3.5. Example royalty asset purchase agreements
3.5.1. Case study 3: Royalty asset: DRI Capital - NPS Pharmaceuticals

Chapter 4 - Leading asset purchase deals

4.1. Introduction
4.2. Top asset purchase deals by value
4.3. Most active asset purchase dealmakers
4.4. Big pharma asset purchase deal activity
4.5. Big biotech asset purchase deal activity

Chapter 5 - Big pharma asset purchase deals

5.1. Introduction
5.2. How to use asset purchase deals
5.3. Big pharma company asset purchase deal profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Kyowa Hakko Kirin
Lundbeck
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novartis Consumer Health
Novo Nordisk
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 6 - Big biotech company asset purchase deals

6.1. Introduction
6.2. How to use big biotech partnering deals
6.3. Big biotech asset purchase partnering company profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Cangene
Dendreon
Elan
Emergent BioSolutions
Galapagos
Ipsen
Optimer
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
SciClone Pharmaceuticals
Spectrum Pharmaceuticals
ViroPharma

Chapter 7 - Asset purchase contracts directory

7.1. Introduction
7.2. Company A-Z
7.3. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

7.4. By therapeutic target

Anaesthetics
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Public health
Respiratory
Sexual health

7.5. By technology type

Analysis
Antibiotics
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Bioprocessing
Blood products
Cell culture
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Enviromental
Equipment
Facilities
Gene therapy
Genomics
Implant
Industrial chemicals
Nanotechnology
Natural product
Oligonucleotide
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Vaccines

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Reports
Order Form - Reports

Appendices

Appendix 1: Asset purchase deals by Company A-Z
Appendix 2: Asset purchase deals by therapy area
Appendix 3: Asset purchase deals by stage of development at signing
Appendix 4: Asset purchase deals by technology type

TABLE OF FIGURES

Figure 1: Definition of assets purchased
Figure 2: Trends in asset purchase deal announcements, 2009-2014
Figure 3: Leading royalty asset investors
Figure 4: Recent leading royalty asset purchase agreements
Figure 5: Leading IP auction companies
Figure 6: Components of the asset purchase deal structure
Figure 7: Components of the royalty asset purchase deal structure
Figure 8: Top asset purchase deals by value since 2009
Figure 9: Most active asset purchase dealmakers 2009-2014
Figure 10: Bigpharma - top 50 - asset purchase deals 2009 to 2014
Figure 11: Big pharma asset purchase deal frequency - 2009 to 2014
Figure 12: Big biotech - top 50 - asset purchase deals 2009 to 2014
Figure 13: Big biotech asset purchase deal frequency - 2009 to 2014

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

  • $ 34 500
  • Industry report
  • July 2014
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2014 Strategies for the Global Microbiology Testing Market” is a new seven-country strategic analysis ...

The 2014 World%s Leading Diagnostic Imaging Companies

The 2014 World%s Leading Diagnostic Imaging Companies

  • $ 14 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.